Gómez-Caro Abel, Badia Joan Ramon, Ausin Pilar
Instituto del Tórax, Hospital Clínic de Barcelona, Universidad de Barcelona, CIBER de enfermedades respiratorias CIBERES, España.
Arch Bronconeumol. 2010 Oct;46(10):531-7. doi: 10.1016/j.arbres.2010.05.005. Epub 2010 Jun 17.
Despite improvements in ventilation support techniques, lung protection strategies, and the application of new support treatment, acute respiratory distress syndrome continues to have a high mortality rate. Many strategies and treatments for this syndrome have been investigated over the last few year. However, the only therapeutic measure that has systematically shown to be able to improve survival is that of low volume lung protective ventilation. Thus, using a low tidal volume prevents added lung damage by the same mechanical ventilation that is essential for life support. In this context, the use of extracorporeal lung assist systems is considered an exceptional use rescue treatment in extreme cases. On the other hand, it could be a potentially useful complementary method for an ultra-protective ventilation strategy, that is, by using even lower tidal volumes. The currently available extracorporeal lung assist systems are described in this article, including high flow systems such as traditional extracorporeal membrane oxygenation, CO₂ removal systems (interventional lung assist or iLA, with or without associated centrifugal pumps), and the new low flow and less invasive systems under development. The aim of this review is to update the latest available clinical and experimental data, the indications for these devices in adult respiratory distress syndrome (ARDS), and their potential indications in other clinical situations, such as the bridge to lung transplantation, multiple organ dysfunction syndrome, or COPD.
尽管通气支持技术、肺保护策略及新的支持治疗方法有所改进,但急性呼吸窘迫综合征的死亡率仍然很高。在过去几年里,针对该综合征开展了许多策略和治疗方法的研究。然而,唯一经系统证明能够提高生存率的治疗措施是小潮气量肺保护性通气。因此,采用小潮气量可防止维持生命所必需的机械通气造成额外的肺损伤。在此背景下,体外肺辅助系统的应用被视为极端情况下的一种特殊的挽救治疗方法。另一方面,对于超保护性通气策略,即采用更低潮气量时,它可能是一种潜在有用的辅助方法。本文介绍了目前可用的体外肺辅助系统,包括传统体外膜肺氧合等高流量系统、二氧化碳清除系统(介入性肺辅助或iLA,有无相关离心泵)以及正在研发的新型低流量和微创系统。本综述的目的是更新最新的临床和实验数据、这些设备在成人呼吸窘迫综合征(ARDS)中的应用指征及其在其他临床情况中的潜在应用指征,如作为肺移植的过渡、多器官功能障碍综合征或慢性阻塞性肺疾病(COPD)。